Equity/Index & Cross Asset Volatility Specialist, Cameron Design

Jay Cameron

Equity/Index & Cross Asset Volatility Specialist

Cameron Design

We specialize in financial products and volatility. Our strategies balance speed, data, and risk control to capture opportunities across global markets. Our research leverages AI and data analytics to continuously refine our algorithms and adapt to evolving market dynamics.

Equity Derivatives

<ul>
<li>BillionToOne leverages its patented Quantitative Counting Technology (QCT) to achieve superior disease detection in molecular diagnostics, positioning the firm as a leader in prenatal  testing, carrier screening, oncology testing markets.</li>
<li>Demonstrating strong operational efficiency, BLLN achieved a 113% year-over-year revenue increase in 2024 and a 65% gross margin in the first half of 2025, suggesting a path to sustained profitability.</li>
<li>With a successful public debut, the recent price pullback, and an additional oncology pipeline slated for 2026, the company presents an intriguing opportunity for strategic long-term position building.</li>
</ul>


BillionToOne leverages its patented Quantitative Counting Technology (QCT) to achieve superior disease detection in molecular diagnostics, positioning the firm as a leader in prenatal  testing, carrier screening, oncology testing markets.
Demonstrating strong operational efficiency, BLLN achieved a 113% year-over-year revenue increase in 2024 and a 65% gross margin in the first half of 2025, suggesting a path to sustained profitability.
With a successful public debut, the recent price pullback, and an additional oncology pipeline slated for 2026, the company presents an intriguing opportunity for strategic long-term position building.


BillionToOne: More Than 60% Above IPO Pricing, What’s Ahead?

Private Markets, Angel and Secondary Investing, Sacra

Sacra

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

<ul><li>Sacra estimates BillionToOne hit $153M in revenue in 2024, more than doubling from $72M in 2023, representing 112% year-over-year growth.</li><li>The company generates revenue primarily through its prenatal testing business, which has captured 15% market share in the US and is profitable.</li><li>BillionToOne reached a valuation of over $1 billion following a $130 million Series D financing round.</li></ul>

Sacra estimates BillionToOne hit $153M in revenue in 2024, more than doubling from $72M in 2023, representing 112% year-over-year growth.The company generates revenue primarily through its prenatal testing business, which has captured 15% market share in the US and is profitable.BillionToOne reached a valuation of over $1 billion following a $130 million Series D financing round.

<ul><li>Sacra estimates that Benchling hit $210M in annual recurring revenue (ARR) in May 2024, up from $185M at the end of 2023.</li><li>Benchling&#39;s customer base expanded from 410 in 2020 to 1,200 as of May 2024.</li><li>Benchling drives this expansion through a combination of user growth within accounts (i.e., adding more seats) and upselling additional modules and capabilities.</li></ul>

Sacra estimates that Benchling hit $210M in annual recurring revenue (ARR) in May 2024, up from $185M at the end of 2023.Benchling&#39;s customer base expanded from 410 in 2020 to 1,200 as of May 2024.Benchling drives this expansion through a combination of user growth within accounts (i.e., adding more seats) and upselling additional modules and capabilities.

US-EU Index Rebalances / Quantitative Researcher

Dimitris Ioannidis

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Index Rebalance

<ul>
<li>
<a href="https://www.smartkarma.com/entities/billiontoone-inc" target="_blank" data-smartkarma-citation="entities:45919:1" rel="noopener">BillionToOne (BLLN US)</a> went public on 6 November 2025 on Nasdaq and has a current market cap of $4bn following a price jump of ~50% above the offer price.</li>
<li>Initial exclusion from US and Global indices is expected due to insufficient free float and public voting rights.</li>
<li>Delayed inclusion in US and Global indices is forecasted for September 2026 and onwards, following lock-up expiry which increases free float and public voting rights above thresholds.</li>
</ul>



BillionToOne (BLLN US) went public on 6 November 2025 on Nasdaq and has a current market cap of $4bn following a price jump of ~50% above the offer price.
Initial exclusion from US and Global indices is expected due to insufficient free float and public voting rights.
Delayed inclusion in US and Global indices is forecasted for September 2026 and onwards, following lock-up expiry which increases free float and public voting rights above thresholds.


BillionToOne (BLLN US): Delayed US & Global Index Inclusion Following Lock‑up

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>BillionToOne priced above range at $60.00 and opened at $100.00, closing up 81.6% at $108.94.</li>
<li>The deal was more than 20x oversubscribed, driven by strong long-only and healthcare demand</li>
<li>Backed by top-tier investors and partnerships with Johnson &amp; Johnson, BLLN’s profitability and precision platform stood out in a choppy IPO market.</li>
</ul>


BillionToOne priced above range at $60.00 and opened at $100.00, closing up 81.6% at $108.94.
The deal was more than 20x oversubscribed, driven by strong long-only and healthcare demand
Backed by top-tier investors and partnerships with Johnson &amp; Johnson, BLLN’s profitability and precision platform stood out in a choppy IPO market.


BillionToOne, Inc. (BLLN): Precision Diagnostics Firm Soars 82% in One of 2025’s Best IPO Debuts

United States

BillionToOne, Inc. operates as a diagnostics company. The Company provides quantitative counting templates that detects genetic disorders in the developing baby from maternal blood, as well as invents in the patent-pending molecular counter platform, which increases the resolution of cell-free DNA detection. BillionToOne serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BillionToOne (BLLN US)

BillionToOne: More Than 60% Above IPO Pricing, What’s Ahead?

With 2Q earnings coming out this week, we revisit the March surprise: 2025 FY $305M Revenue was 100% YoY. FY2025, there was growth in both...

Jay Cameron

Primer: BillionToOne - 18 May 2026

Genetic testing tool for prenatal screening and cancer therapy selection via blood samples

Sacra

Primer: Benchling - 12 Oct 2026

Software for biotech teams to design, document, and manage scientific experiments and samples

Sacra